FundedIQ
Biotechnology

Evoke Pharma: Funding, Investors & Team (Sep 2026)

Evoke Pharma, Inc. is a privately held specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases. The Company was established by experienced specialty pharmaceutical executives with a successful track record of acquiring, developing, registering, and marketing pharmaceutical products in the US. Evoke has concentrated on the gastroenterology field due to the significant unmet medical needs, the opportunity to improve known products and its focused physician base. Despite the relatively high number of patients suffering from gastrointestinal diseases and disorders, there are only about 12,000 gastroenterologists in the U.S. These physicians conduct over 31 million patient visits and write almost 40 million prescriptions each year valued at $4.8 billion. Also, GI diseases may limit or alter the effectiveness of traditional oral therapies due to the disease for which the product is intended to treat. By developing enhanced versions of currently approved drug products, through novel delivery formats or formulations, Evoke intends to provide patients additional treatment options. Evoke's lead product candidate, EVK-001, is in late stage clinical testing. The company has exclusive rights to a novel formulation and delivery of a currently marketed GI product. The product is intended for the treatment of diabetic gastroparesis. Evoke has advanced its product development activities by leveraging several corporate relationships with many external clinical, CMC, and regulatory experts. Evoke plans to continue this strategy of developing acquired products in partnership with various global organizations depending upon new acquisitions and appropriate asset investment.

evokepharma.com LinkedIn San Diego, United States 11-50 employees
Total raised
$7.5M
Rounds
1
Latest
Undisclosed round
Feb 2024

Evoke Pharma has raised $7.5M across 1 funding round on record, the most recent an undisclosed round of $7.5M announced in Feb 2024.

That round is in line with the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Evoke Pharma Company Profile and Key Stats

Total funding raised
$7.5M
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$7.5M in Feb 2024
Employees
11-50
reported band
Headquarters
San Diego, United States

Latest funding round on record: Feb 2024.

Evoke Pharma Funding Rounds

Date
Round
Amount
Undisclosed round
$7.5M

Evoke Pharma Founders and Leadership Team

Name
Role
Contact
Matthew J Donofrio
Founder
Locked

Contact details for the Evoke Pharma team: 1 of 1 has an email address on file.

Start 14-day free trial →

Evoke Pharma Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M

Evoke Pharma's latest round of $7.5M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Evoke Pharma in Biotechnology and San Diego

Companies Similar to Evoke Pharma

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Evoke Pharma Funding FAQs

What does Evoke Pharma do?

Evoke Pharma, Inc. is a privately held specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases. The Company was established by experienced specialty pharmaceutical executives with a successful track record of acquiring, developing, registering, and marketing pharmaceutical products in the US. Evoke has concentrated on the gastroenterology field due to the significant unmet medical needs, the opportunity to improve known products and its focused physician base. Despite the relatively high number of patients suffering from gastrointestinal diseases and disorders, there are only about 12,000 gastroenterologists in the U.S. These physicians conduct over 31 million patient visits and write almost 40 million prescriptions each year valued at $4.8 billion. Also, GI diseases may limit or alter the effectiveness of traditional oral therapies due to the disease for which the product is intended to treat. By developing enhanced versions of currently approved drug products, through novel delivery formats or formulations, Evoke intends to provide patients additional treatment options. Evoke's lead product candidate, EVK-001, is in late stage clinical testing. The company has exclusive rights to a novel formulation and delivery of a currently marketed GI product. The product is intended for the treatment of diabetic gastroparesis. Evoke has advanced its product development activities by leveraging several corporate relationships with many external clinical, CMC, and regulatory experts. Evoke plans to continue this strategy of developing acquired products in partnership with various global organizations depending upon new acquisitions and appropriate asset investment.

How much funding has Evoke Pharma raised?

Evoke Pharma has raised $7.5M across 1 round on record. The most recent is an undisclosed round of $7.5M announced in Feb 2024.

When did Evoke Pharma last raise funding?

Evoke Pharma's most recent funding round on record is an undisclosed round of $7.5M, announced in Feb 2024.

Who founded Evoke Pharma?

FundedIQ lists Matthew J Donofrio (Founder) at Evoke Pharma.

Where is Evoke Pharma headquartered?

Evoke Pharma is based in San Diego, California, United States.

How many employees does Evoke Pharma have?

Evoke Pharma is in the 11-50 employee band.

How does Evoke Pharma's funding compare to other Biotechnology startups?

Evoke Pharma's latest round of $7.5M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Evoke Pharma Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Evoke Pharma is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.